Palatin Technologies(PTN) - 2024 Q4 - Annual Results

EX-99.1 2 ptn_ex991.htm PRESS RELEASE EXHIBIT 99.1 Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones · Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1) o Patient Dosing Commenced 3Q Calendar Year 2024 o Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024 o Topline Results Expected 1Q Calendar Year 2025 · Dry Eye ...